BSX - iRhythm fade continues as competitor talks about reimbursement issues

iRhthm (IRTC) fell for a second day, dropping 2.7%, following its 40% plunge on Friday, as a competitor talked about "headwinds" from the Medicare reimbursement issues on a conference call earlier.Boston Scientific (BSX), which last month agreed to buy IRTC competitor Preventice, said on its earnings conference call that it expects a headwind related to new reimbursements for long-term Holter monitor device."There is obviously a headwind with long-term Holter and I think there will be quite a few discussions on that aspect in the future,"  BSX executive said on the call.I would call the reimbursement situation "fluid and I would expect to see additional meetings in the near future and we'll see where that plays out," BSX added."We don't think the current reimbursement level is consistent with clinical results effectiveness and amount of work in labor required for long-term Holter, but I think that reimbursement position will be fluid," BSX executive

For further details see:

iRhythm fade continues as competitor talks about reimbursement issues